Literature DB >> 3415422

Dose of fluphenazine, familial expressed emotion, and outcome in schizophrenia. Results of a two-year controlled study.

G E Hogarty1, J P McEvoy, M Munetz, A L DiBarry, P Bartone, R Cather, S J Cooley, R F Ulrich, M Carter, M J Madonia.   

Abstract

Issues regarding the side effects of antipsychotic medication and the possible contribution of the environment to dose requirements led to a two-year controlled dosage study of maintenance antipsychotic medication and familial environment among recently discharged schizophrenic patients. Seventy stable patients, living in high- or low-expressed emotion (EE) households, were randomized, double blind, to receive a standard dose of fluphenazine decanoate (average, 25 mg every two weeks) or a minimal dose representing 20% of the dose prescribed (average, 3.8 mg every two weeks). No differences in relapse were observed among dose, EE, or dose and EE. Patients in the minimal dose/high-EE condition experienced more minor but aborted episodes in year 2. Side effects were fewer on the minimal dose after one year, and low-EE patients were better adjusted than high-EE patients. Over time, minimal-dose recipients were significantly more improved in their instrumental and interpersonal role performance than were standard-dose recipients.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3415422     DOI: 10.1001/archpsyc.1988.01800330021002

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  21 in total

Review 1.  Dose response and atypical antipsychotics in schizophrenia.

Authors:  Bruce J Kinon; Jonna Ahl; Virginia L Stauffer; Angela L Hill; Peter F Buckley
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 2.  Supportive therapy for schizophrenia.

Authors:  Lucy A Buckley; Nicola Maayan; Karla Soares-Weiser; Clive E Adams
Journal:  Cochrane Database Syst Rev       Date:  2015-04-14

3.  The stress process perspective and adaptation of people with schizophrenia--an exploratory study.

Authors:  Yves Lecomte; Céline Mercier
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2005-02       Impact factor: 4.328

4.  Effects of risperidone and olanzapine dose reduction on cognitive function in stable patients with schizophrenia: an open-label, randomized, controlled, pilot study.

Authors:  Hiroyoshi Takeuchi; Takefumi Suzuki; Gary Remington; Robert R Bies; Takayuki Abe; Ariel Graff-Guerrero; Koichiro Watanabe; Masaru Mimura; Hiroyuki Uchida
Journal:  Schizophr Bull       Date:  2013-07-01       Impact factor: 9.306

5.  Low dose vs standard dose of antipsychotics for relapse prevention in schizophrenia: meta-analysis.

Authors:  Hiroyuki Uchida; Takefumi Suzuki; Hiroyoshi Takeuchi; Tamara Arenovich; David C Mamo
Journal:  Schizophr Bull       Date:  2009-11-27       Impact factor: 9.306

6.  Management of schizophrenia : an update.

Authors:  P Kulhara
Journal:  Indian J Psychiatry       Date:  1998-04       Impact factor: 1.759

Review 7.  Pharmacological treatment of patients with schizophrenia. Past and present problems and potential future therapy.

Authors:  D A Johnson
Journal:  Drugs       Date:  1990-04       Impact factor: 9.546

8.  Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial.

Authors:  Joseph P McEvoy; Matthew Byerly; Robert M Hamer; Rosalie Dominik; Marvin S Swartz; Robert A Rosenheck; Neepa Ray; J Steven Lamberti; Peter F Buckley; Tania M Wilkins; T Scott Stroup
Journal:  JAMA       Date:  2014-05-21       Impact factor: 56.272

9.  Factors associated with successful antipsychotic dose reduction in schizophrenia: a systematic review of prospective clinical trials and meta-analysis of randomized controlled trials.

Authors:  Hideaki Tani; Shotaro Takasu; Hiroyuki Uchida; Takefumi Suzuki; Masaru Mimura; Hiroyoshi Takeuchi
Journal:  Neuropsychopharmacology       Date:  2019-11-26       Impact factor: 7.853

10.  Mechanisms of action of antipsychotic drugs of different classes, refractoriness to therapeutic effects of classical neuroleptics, and individual variation in sensitivity to their actions: Part I.

Authors:  R Miller
Journal:  Curr Neuropharmacol       Date:  2009-12       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.